

Date: 11<sup>th</sup> November, 2025

To, <b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1 Block G, Bandra Kurla Complex Bandra [E], Mumbai – 400051 NSE Scrip Symbol: <b>KRONOX</b>	To, <b>BSE Limited</b> 25 <sup>th</sup> Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 BSE Scrip Code: <b>544187</b>
--	--

**Subject: Outcome of Board Meeting held on Tuesday, 11<sup>th</sup> November, 2025.**

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that, Board of Directors at their meeting held today i.e. on **Tuesday, 11<sup>th</sup> November, 2025** have considered, approved and took on record the followings:


1. Statement of Standalone Unaudited Financial Results for the quarter and half year ended on 30<sup>th</sup> September, 2025 along with Statement of Assets and Liabilities as at 30<sup>th</sup> September, 2025 and the Cash Flow Statement for the quarter and half-year ended on 30<sup>th</sup> September, 2025
2. Independent Auditors' Limited Review Report on Financial Results.

The Meeting of Board of Directors commenced at 3:30 p.m. and concluded at 4.45 p.m.

Kindly take the aforesaid information on your record and oblige.

Thanking you

For **KRONOX Lab Sciences Limited**



**Nikhil Goswami**  
Company Secretary & Compliance Officer  
Membership No. A68272



## KRONOX LAB SCIENCES LIMITED

Corporate Office Address : Block No. 284, Village : Dabhasa, Taluka : Padra, Dist. : Vadodara, Gujarat State - 391 440.  
Registered Office Address : Block No. 138, Village : Ekalbara, Taluka : Padra, Dist. : Vadodara, Gujarat State - 391 440.  
Phone No. : +91 2662 299002  
Email : [info@kronoxlabsciences.com](mailto:info@kronoxlabsciences.com),  
CIN : L24117GJ2008PLC055460  
Webside : [www.kronoxlabsciences.com](http://www.kronoxlabsciences.com)

## KRONOX LAB SCIENCES LIMITED

Regd. Office: Block No. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 Gujarat  
 email: cs@kronoxlabsciences.com ; CIN: L24117GJ2008PLC055460  
 Quarterly & Half Year ended Financial Result by Companies Other than Banks  
 Unaudited Financial Results for the Quarter and Half Year ended 30.09.2025

(Rs In Lakhs)

Sr.No	Particulars	Quarter Ended			Half Year ended		Year Ended
		30.09.2025	30.09.2024	30.06.2025	30.09.2025	30.09.2024	31.03.2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	<b>INCOME FROM OPERATION</b>						
1	Revenue from Operation	2,553.32	2,485.91	2,428.65	4,981.97	5,005.17	10,019.39
2	Other Income	104.21	36.06	87.32	191.53	79.28	252.60
3	<b>Total Income</b>	<b>2,657.53</b>	<b>2,521.97</b>	<b>2,515.97</b>	<b>5,173.50</b>	<b>5,084.46</b>	<b>10,271.99</b>
	<b>EXPENSES</b>						
a	Cost of Materials Consumed	1,021.42	1,087.64	1,287.23	2,308.65	2,316.73	4,867.00
b	Changes in Inventories of Finished Goods, Work in progress and Stock-In-Trade	114.97	41.86	(111.69)	(8.11)	150.11	225.33
c	Employee Benefits expenses	184.01	116.31	178.40	362.41	233.48	475.36
d	Finance Costs	3.92	-	-	3.92	-	-
e	Depreciation and amortisation Expenses	46.84	34.16	40.06	86.90	67.40	138.20
f	Other Expenses	368.37	359.70	277.92	646.29	603.64	1,139.02
	<b>TOTAL EXPENSES</b>	<b>1,739.53</b>	<b>1,639.67</b>	<b>1,671.92</b>	<b>3,400.06</b>	<b>3,371.37</b>	<b>6,844.91</b>
5	<b>Profit before Tax</b>	<b>918.00</b>	<b>882.30</b>	<b>844.05</b>	<b>1,773.44</b>	<b>1,713.09</b>	<b>3,427.08</b>
6	<b>Tax Expenses</b>						
a	Current Tax	250.00	225.53	218.60	468.60	442.19	886.41
b	Tax Expenses relating to prior years	-	-	-	-	-	1.91
c	Deferred Tax	0.37	9.46	(2.42)	(2.05)	8.57	(7.95)
d	Tax Expenses/Refunds relating to prior years	-	-	-	-	-	-
7	<b>Profit after Tax for the Period</b>	<b>667.62</b>	<b>647.31</b>	<b>627.87</b>	<b>1,306.89</b>	<b>1,262.32</b>	<b>2,546.70</b>
8	<b>Other Comprehensive Income</b>						
a	Item that will not be reclassified to profit or loss						
	(i) Defined benefit Plan liability/assets	7.94	6.01	3.25	11.19	10.95	24.91
	(ii) Tax impact on above item	(2.00)	(1.51)	(0.82)	(2.82)	(2.76)	(6.27)
b	Item that will be reclassified to profit or loss						
	(i) Exchange difference arising on translation of foreign operations	-	-	-	-	-	-
c	Exceptional Items	-	-	-	-	-	-
9	<b>Total Comprehensive Income for the period</b>	<b>673.56</b>	<b>651.80</b>	<b>630.30</b>	<b>1,315.26</b>	<b>1,270.52</b>	<b>2,565.34</b>
10	Paid up share capital(FV Rs.10/- per share.) OTHER EQUITY	3710.4	3710.4	3710.4	3710.4	3710.4	3710.4 5,300.10
11	<b>Earning per equity share (In Rupees) (F V Rs.10/- per share) (Basic &amp; Diluted)</b>	<b>1.82</b>	<b>1.76</b>	<b>1.70</b>	<b>3.54</b>	<b>3.42</b>	<b>6.91</b>

**Notes:**

- The above Unaudited results have been prepared in accordance with Indian Accounting Standard (IND AS) notified under section 133 of the companies Act, 2013, read together with relevant rules issued there under and other accounting principles generally accepted in India.
- The above results, have been reviewed by the Statutory Auditors, recommended by the Audit Committee and Approved by the Board of Directors in their meeting held on 11th November, 2025.  
The Company is having only one reportable segment under Ind As-108 on "Operating Segments" i.e. manufacturing of High Purity Speciality Fine chemical.
- The previous quarters'/years' figures have been regrouped/rearranged wherever necessary to make it comparable with the current quarter/year.
- The Company has done Initial Public Offering which was 100% Offer for Sale (OFS) hence Company is not required to file Statement of deviation or variation under Regulation 32 of SEBI (LODR) Regulation, 2015.
- The Company has given Final Dividend @ 5% for the FY 24-25 in the month of September 2025.

Date: 11/11/2025  
Place: Vadodara



For and on behalf of the Board of  
KRONOX LAB SCIENCES LIMITED

*Jogindersingh Jaswal*

JOGINDERSINGH JASWAL  
Managing Director  
DIN: 02385809





**Independent Auditor's Review Report on the Unaudited Standalone Financial Results of KRONOX LAB SCIENCES LIMITED for quarter and half year ended September 30, 2025 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

**Review report to  
The Board of Directors  
KRONOX LAB SCIENCES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **KRONOX LAB SCIENCES LIMITED** for the quarter ended 30<sup>th</sup> September 2025 and half year ended 30<sup>th</sup> September 2025 ("the Statement") attached herewith.

The Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance



with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Mahesh Udhwani & Associates**  
**Chartered Accountants**  
**FRN :129738W**

*M. A. Udhwani*

**Mahesh Udhwani**  
**Partner**

**M.N:- 047328**

**UDIN: 25047328BMHYLE5096**

**Place: Vadodara**

**Date : 11/11/2025**



**KRONOX LAB SCIENCES LIMITED**  
**CIN: L24117GJ2008PLC055460**  
**Balance Sheet as at 30th September'2025**

Rs. In Lakhs

Particulars	Notes	30th September,2025	31st March,2025
<b>Assets</b>			
<b>I. Non-current assets</b>			
(a) Property, plant and equipment	2	2,971.34	2,785.60
(b) Capital work-in-progress	3	79.81	75.97
<b>(c) Financial assets</b>			
(i) Investments	4	2.50	2.50
(ii) Other Financial Asset	5	70.07	648.10
(d) Deferred Tax Asset (net)	6	39.05	39.82
		<b>3,162.77</b>	<b>3,551.99</b>
<b>II. Current assets</b>			
(a) Inventories	7	756.88	637.19
<b>(b) Financial assets</b>			
(i) Investments			
(ii) Trade Receivables	8	2,052.72	1,988.83
(iii) Cash and cash equivalent	9	265.04	303.55
(iv) Bank balances other than(iii) above	9A	996.83	540.12
(v) Other Financial Asset	10	3,955.04	2,824.67
(c) Other current assets	11	78.64	36.29
		<b>8,105.15</b>	<b>6,330.64</b>
<b>Total assets</b>		<b>11,267.92</b>	<b>9,882.63</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
(a) Equity share capital	12	3,710.40	3,710.40
(b) Other equity	13	6,430.01	5,300.10
<b>Total Equity</b>		<b>10,140.41</b>	<b>9,010.50</b>
<b>Liabilities</b>			
<b>I. Non-current liabilities</b>			
<b>(a) Financial liabilities</b>			
(i) Borrowings	14	131.18	
(a) Provisions	15	4.58	2.62
		<b>135.76</b>	<b>2.62</b>
<b>II. Current liabilities</b>			
<b>(a) Financial liabilities</b>			
(i) Borrowings	16	130.22	
(i) Trade payables	17		
Total outstanding dues of micro enterprise and small enterprise		247.82	256.42
Total outstanding dues of creditors other than micro enterprise and small enterprise		504.70	471.28
(b) Other current liabilities	18	46.08	79.78
(c) Provisions	19	72.71	49.63
(d) Current Tax Liabilities (Net)	20	(9.78)	12.40
		<b>991.75</b>	<b>869.51</b>
<b>Total equity and liabilities</b>		<b>11,267.92</b>	<b>9,882.63</b>
Significant accounting policies	1		

For and on behalf of the Board of Directors



*Jogindersingh Jaswal*  
**Jogindersingh Jaswal**  
**(Managing Director)**  
**DIN :02385809**



Date : 11-11-2025  
Place: Vadodara

## KRONOX LAB SCIENCES LIMITED

CIN: L24117GJ2008PLC055460

## Cash flow Statement for the period April,2025 to September,2025

Rs. In Lakhs

Particulars		30th September,2025	31st March,2025
<b>A</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
	Net profit before tax	1,773.45	3,427.08
	<u>Adjustments for:</u>		
	Add : Depreciation and amortisation	86.90	138.20
	Allowance for credit losses Financial Asset		-
	Interest Income	(121.24)	(177.59)
	Accrued Defined Benefit Plan Liability	13.92	26.67
	Dividend Income	-	(0.03)
	<b>Operating Profit before Working Capital Changes</b>	<b>1,753.03</b>	<b>3,414.34</b>
	<u>Adjustments for:</u>		
	Trade Receivables	-63.90	-224.18
	Other Current Assets	-42.35	378.30
	Inventories	-119.69	288.07
	Non current assets		0.00
	Trade payables & Provisions	35.94	66.86
	Other Current and non current Liabilities	-44.70	34.60
	<b>Cash Generated from Operations</b>	<b>(234.70)</b>	<b>543.64</b>
	Less : Direct Taxes paid	468.60	888.32
	<b>Net Cash generated from operating activities (i)</b>	<b>1,049.73</b>	<b>3,069.66</b>
<b>B</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
	Purchase of Property, plant and Equipment incl.CWIP	-303.04	-310.43
	Bank Deposits (placed)/matured	-1009.05	-2706.58
	Security Deposits (placed)/matured		0.00
	Sale of fixed assets	26.56	0.00
	Interest Income	121.24	177.59
	Dividend Income	-	0.03
	<b>Net cash generated from investing activities (ii)</b>	<b>(1,164.30)</b>	<b>(2,839.39)</b>
<b>C</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
	Interest Expense	-	-
	Payment of Dividends	-185.35	(185.35)
	Proceeds From borrowings	261.40	
	<b>Net cash generated from financial activities (iii)</b>	<b>76.05</b>	<b>(185.35)</b>
	<b>Net change in cash and cash equivalents (i+ii+iii)</b>	<b>(38.51)</b>	<b>44.91</b>
	Cash and cash equivalents at the beginning of the year	303.55	258.64
	<b>Cash and cash equivalents at the end of the year*</b>	<b>265.04</b>	<b>303.55</b>
	<b>*Cash &amp; cash equivalents includes:</b>		
	Cash in hand	1.70	2.32
	Balances with Scheduled Bank	263.34	301.22

For and on behalf of the Board of Directors

Date : 11-11-2025  
Place : Vadodara

*Jogindersingh Jaswal*  
Jogindersingh Jaswal  
(Managing Director)  
DIN : 02385809

